Core Points - Chuaning Bio announced the approval of a proposal to issue non-financial corporate debt financing instruments at its board meeting on April 18, 2025, and the annual shareholders' meeting on May 13, 2025 [1] - The company plans to apply for registration to issue various types of debt financing tools, including but not limited to short-term financing bonds, medium-term notes, and super short-term financing bonds, with a total registration amount not exceeding 1 billion yuan for each product type [1] - The company has received a registration acceptance notice from the China Interbank Market Dealers Association, allowing it to register medium-term notes with a total amount of 1 billion yuan, valid for two years from the date of the notice [1] Company Actions - The company will issue medium-term notes with a registration amount of 1 billion yuan, underwritten by Industrial Bank Co., Ltd. [1] - The company can issue medium-term notes in installments during the validity period of the registration and must disclose the issuance results through approved channels [1]

Group 1 - The company, Chuaning Bio (301301.SZ), has received a registration notice from the trading association for its medium-term notes [1] - The registered amount for the medium-term notes is 1 billion yuan, valid for 2 years from the date of the notice [1] - The lead underwriter for the issuance is Industrial Bank Co., Ltd., and the company can issue the notes in tranches during the registration period [1]

Group 1 - The company, Chuaning Bio (301301.SZ), has received a registration notice from the trading association for its medium-term notes [1] - The registered amount for the medium-term notes is 1 billion yuan, valid for 2 years from the date of the notice [1] - The lead underwriter for the issuance is Industrial Bank Co., Ltd., and the company can issue the notes in tranches during the registration period [1]

Core Viewpoint - Chuaning Bio (301301.SZ) has received a registration notice from the Association of Dealers, allowing the company to register medium-term notes amounting to 1 billion yuan, valid for two years from the date of the notice [1] Group 1 - The company has been granted a registration amount of 1 billion yuan for its medium-term notes [1] - The registration validity period is set for two years from the date of the notice issued by the Association of Dealers [1]

Group 1 - The company has received a registration notice from the trading association, approving the registration of its medium-term notes [1] - The registered amount is 1 billion yuan, and the registration quota is valid for two years from the date of the notice [1] - Industrial Bank Co., Ltd. is the lead underwriter for the issuance of the medium-term notes [1] Group 2 - The company plans to issue the medium-term notes in phases based on market conditions and the requirements of the notice [1] - The company will fulfill its information disclosure obligations in a timely manner [1]

证券代码：301301 证券简称：川宁生物 公告编号：2025-037 伊犁川宁生物技术股份有限公司 关于中期票据获准注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 伊犁川宁生物技术股份有限公司（简称"公司"）分别于 2025 年 4 月 18 日召开的第二届董事会第九次会议及 2025 年 5 月 13 日召开的 2024 年年度股东 大会审议通过了《关于公司及所属子公司发行非金融企业债务融资工具的议案》， 同意公司及子（分）公司向中国银行间市场交易商协会（简称"交易商协会"） 申请注册发行非金融企业债务融资工具，发行品种包括但不限于短期融资券、中 期票据、中小企业集合票据、超短期融资券等相关监管部门认可的类型，其中不 受交易商协会注册额度限制的债务融资工具，每一种类产品的注册总额不超过 10 亿元。具体情况详见公司于 2025 年 4 月 22 日在中国证券监督管理委员会指 定的创业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）披露的相关公 告。 近日，公司收到交易商协会出具的《接受注册通知书》（中市协注〔2025 ...

Group 1 - The core viewpoint of the article highlights the growth of industrial enterprises in the Xinjiang Uygur Autonomous Region, with a total of 5,381 enterprises reported from January to July 2025, marking an increase of 465 enterprises compared to the same period last year, representing a year-on-year growth of 9.46% [1][1][1] - The report indicates that the number of industrial enterprises in Xinjiang accounts for 1.03% of the national total [1][1][1] - The data presented is sourced from the National Bureau of Statistics and organized by Zhiyan Consulting, a leading industry consulting firm in China [1][1][1] Group 2 - The article references various listed companies related to the industrial sector, including Guanghui Energy, New Natural Gas, and others, indicating potential investment opportunities [1][1][1] - Zhiyan Consulting has been engaged in industry research for over a decade, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1][1][1] - The report titled "2025-2031 China Industrial Cloud Industry Market Deep Assessment and Investment Opportunity Forecast" is mentioned, suggesting a focus on future market trends and investment potential [1][1][1]

3、本公告中百分比例均保留 4 位小数，若其各分项数值之和与合计数值存 在尾差，均为四舍五入原因造成。 一、会议召开和出席情况 （一）召开情况 1、股东大会届次：2025 年第二次临时股东大会 证券代码：301301 证券简称：川宁生物 公告编号：2025-036 伊犁川宁生物技术股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 2、股东大会的召集人：公司董事会 3、股东大会的主持人：董事长刘革新先生 4、会议召开时间： （1）现场会议召开时间：2025 年 9 月 10 日 15:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 9 月 10 日 9:15-9:25、9:30-11:30 和 13:00-15:00 期间任意时间；通 过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 9 月 10 日 9:15-15:00 期间任意时间。 5、现场会议 ...

四川省成都市高新区天府大道北段 966 号天府国际金融中心南塔 25 层-26 层 邮编：610041 25-26/F, South Tower of Tianfu International Finance Center, 966 North Tianfu Avenue, High-tech Zone, Chengdu, Sichuan 610041, P. R. China 电话/Tel : +86 28 6208 8001 传真/Fax : +86 28 6208 8111 www.zhonglun.com 北京中伦（成都）律师事务所 关于伊犁川宁生物技术股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：伊犁川宁生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）及《上市公司股东会规则》等法律、法规 及规范性文件的规定，北京中伦（成都）律师事务所（以下简称"本所"）指派 律师出席了伊犁川宁生物技术股份有限公司（以下简称"公司"）2025 年第二次 临时股东大会（以下简称"本次股东大会"），并对本次股东大会的相关事 ...

Core Viewpoint - The company expects a stable long-term demand for antibiotics despite a short-term decline in market demand compared to the previous year [1] Antibiotic Intermediates Overview - The market demand for thiocyanate erythromycin remains stable, with a balanced supply and demand [1] - Domestic and international demand for cephalosporin intermediates has decreased year-on-year, but the absence of new large-scale production capacity has allowed the company to optimize production allocation, keeping market prices stable [1] - The demand for penicillin intermediates has declined due to changes in disease prevalence and the introduction of new production capacity, leading to a significant price drop; however, the company anticipates a gradual stabilization of prices as some outdated capacities are shut down and Indian production capacity does not meet expectations [1]